MedTrace Logo

The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients

NCT01213017 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-12-07

No results posted yet for this study

Summary

The purpose of this study is to determine whether Certolizumab pegol can rapidly reduce the inflammatory changes and inhibit erosions on hand and wrist MRI in patients with active moderate to severe rheumatoid arthritis.

Conditions

Interventions

DRUG

certolizumab pegol

400mg at week 0, 2 and 4, followed by 200 mg every two weeks for 52 weeks

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • Oklahoma Medical Research Foundation

    lead OTHER

Principal Investigators

  • Ewa Olech, MD · Oklahoma Medical Research Foundation

  • Norman B Gaylis, MD · Arthritis and Rheumatic Disease Specialties

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-01-31
Completion
2012-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01213017 on ClinicalTrials.gov